Entrar/Registro  
INICIO ENGLISH
 
Dermatología Revista Mexicana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Dermatología Revista Mexicana >Año 2016, No. 1


Fierro-Arias L, López-Gehrke I
Nadifloxacino
Dermatología Rev Mex 2016; 60 (1)

Idioma: Español
Referencias bibliográficas: 42
Paginas: 37-44
Archivo PDF: 588.16 Kb.


Texto completo




RESUMEN

El nadifloxacino es una quinolona de aplicación tópica que cuenta con un amplio espectro antimicrobiano y con utilidad en diversas infecciones superficiales de la piel; tiene especial afinidad por cepas de Propionibacterium acnes, lo que le otorga relevancia en el manejo del acné y actualmente forma parte de la primera elección en algunos esquemas de tratamiento contra esta enfermedad. Sus beneficios y condiciones de eficacia, seguridad y tolerabilidad, como monoterapia y en combinación con otros medicamentos, se han reportado en diversos estudios; en la actualidad se ubica como una herramienta relevante en el arsenal terapéutico del dermatólogo.


Palabras clave: nadifloxacino, acné, infecciones bacterianas de la piel, antibióticos tópicos.


REFERENCIAS

  1. Ishikawa H, Tabusa F, Miyamoto H, et al. Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro- 1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids. Chem Pharm Bull (Tokyo) 1989;37:2103-2108.

  2. Muto N, Mitoh Y, Yamamoto I. Development of a sensitive enzyme immunoassay for OPC-7251, a novel antimicrobial agent for percutaneous application. J Immunoassay 1990;11:1-16.

  3. Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy 2004;50:196-201.

  4. Vogt K, Hermann J, Blume U, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur J Clin Microbiol Infect Dis 1992;11:943-945.

  5. Vogt K, Hahn H, Hermann J, et al. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Drugs 1995;49:266-268.

  6. Kurokawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991;25:674-681.

  7. Alba V, Urban E, Angeles Dominguez M, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents 2009;33:272-275.

  8. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2011;45:3544-3547.

  9. Akamatsu H, Sasaki H, Kurokawa I, et al. Effect of nadifloxacin on neutrophil functions. J Int Med Res 1995;23:19-26.

  10. Kuwahara K, Kitazawa T, Kitagaki H, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005;38:47-55.

  11. Inui S, Toshijumi N, Satoshi I. Modulation of androgen receptor transcriptional activity by anti-acne reagents. J Dermatol Sci 2004;36:97-101.

  12. Kawabata S, Ohguro K, Mukai F, Ohmori K, et al. Bacteriological evaluation of OPC-7251, A new pyridone carboxylic acid antimicrobial agent 1. In vitro antibacterial activity. Chemotherapy 1989;37:1160-1178.

  13. Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Medicamentos de uso humano. CIMA: Centro de información Online de Medicamentos de la AEMPS. Ficha técnica de Nadixa 1% crema. [Consultado en agosto de 2015]. Disponible en: http://www.aemps.gob.es/cima/ pdfs/es/ft/64291/FT_64291.pdf

  14. Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999;9:25-28.

  15. Nishijima S, Kurokawa I, Kawabata S. Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents. J Int Med Res 1996;24:473-477.

  16. Ishida N, Nakaminami H, Noguchi N, et al. Antimicrobial susceptibilities of Propionibacterium acnes isolated from patients with acne vulgaris. Microbiol Immunol 2008;52:621-624.

  17. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001;144:339-346.

  18. Asada Y. Clinical assessment of 1% OPC-7251 cream, a new topical antibacterial agent, in acne vulgaris. Nishinihon J Dermatol 1990;52:790-794.

  19. Gollnick HPM, Vogt K, Hermann J, et al. Topical quinolone OPC-7251: a clinical and microbiological study in acne. Eur J Dermatol 1994;4:210-215.

  20. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006;16:48-55.

  21. Tunca M, Akar A, Ozmen I, Erbil H. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. Int J Dermatol 2010;49:1440-1444.

  22. Schöfer H, Göllner A, Kusche W, Schwantes U. Effectiveness and tolerance of topical nadifloxacin in the therapy of acne vulgaris (grade I-II): results of a non-interventional trail in 555 patients. J App Res 2009:9:44-51.

  23. Jung JY, Kwon HH, Yeom KB, et al. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011;50:350-357.

  24. Guías de diagnóstico y tratamiento del Servicio de Dermatología, Hospital General de México: 1. Acné vulgar. Disponible en: http://www.hgm.salud.gob.mx/descargas/ pdf/area_medica/derma/guias/acne_vulgar.pdf. Consultado 15 agosto 2015.

  25. Gilaberte-Calzada Y. Dermatología pediátrica: ¿qué hay de nuevo en el acné?. Rev Pediatr Aten Primaria 2009;11:S303-316.

  26. Sáenz-Anduaga E, Sánchez-Saldaña L. Antibióticos tópicos. Dermatol Peruana 2005;15:7-20.

  27. Herane MI. Actualización terapéutica en acné vulgaris. Dermatol Pediatr Lat 2005;3:5-19.

  28. Haustein UF, Nenoff P, Hittel N. Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: clinical evaluation in multicenter open trial and in vitro antimicrobiological susceptibility testing. J Dermatol Treat 1997;8:87-92.

  29. Narayanan V, Motlekar S, Kadhe G, Bhagat S. Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies. Dermatol Ther (Heidelb) 2014;4:233-248.

  30. Hayakawa R, Ogino Y, Arisu K, Ninagawa Y. Safety evaluation of topical OPC-7251, synthetic antibacterial agent. Skin Res 1990;32:217-230.

  31. Nenoff P. Acne vulgaris and bacterial skin infections. Review of the topical quinolone nadifloxacin. Expert Rev Dermatol 2006;1:643-654.

  32. Kaminsky A. Actualización del algoritmo terapéutico del acné GILEA-CILAD 2014. Sección: Capítulo del CILAD. PIEL-L Latinoamericana. [Consultado en septiembre del 2015]. Disponible en: http://piel-l.org/blog/wp-content/ uploads//2014/04/ACNE-ALGORITMO-TERAPEUTICO- 2014.pdf

  33. Thiboutot D, Gollnik H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009;60:S1-50.

  34. Nast A, Dréno B, Bettoli B, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012;26:1-29.

  35. Savage LJ, Layton AM. Treating acne vulgaris: systemic, local and combination therapy. Expert Rev Clin Pharmacol 2010;3:563-580.

  36. Wigger-Alberti W, Wilhelm D, Schwantes U, Wilhelm KP. A randomized, double-blind, clinical study investigating the cumulative irritation potential of a nadifloxacin cream combined with an additional treatment of other topical anti-acne products in a 21 day open application test. Presented at the 17th European Academy of Dermatology and Venerology Congress, 17th-21th September 2008, Paris, France.

  37. Wilhelm KP, Wilhelm D, Neumeister C, et al. Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents. Clin Exp Dermatol 2011;37:112-117.

  38. Kobayashi M, Nakwaga T, Fukamachi K, et al. Efficacy of combined topical treatment of acne vulgaris whit adapalene and nadifloxacin: a randomized study. J Dermatol 2011;38:1163-1166.

  39. Takigawa M, Tokura Y, Shimada S, et al. Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris. J Dermatol 2013;40:620-625.

  40. Shah BJ, Sumathy TK, Dhurat RS, et al. Efficacy and tolerability of topical fixed combination of nadifloxacin 1% and adapalene 0.1% in the treatment of mild to moderate acne vulgaris in Indian patients: a multicenter, open-labelled, prospective study. Indian J Dermatol 2014;59:385-389.

  41. Choudhury S, Chatterjee S, Sarkar DK, Dutta RN. Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. Indian J Pharmacol 2011;43:628-631.

  42. Kaur J, Sehgal VK, Gupta AK, Singh SP. A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. Int J Appl Basic Med Res 2015;5:106-110.



>Revistas >Dermatología Revista Mexicana >Año2016, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019